Clinically, this implies that while LST1 reflects chronic inflammatory activation, it achieves greater diagnostic discrimination when combined with tumor-specific markers such as CA9, PBRM1, and HLA-exhaustion signatures. This evidence concerns the gene CA9 and neoplasm.